	US 12,365,720 B2
	Etanercept variants with improved therapeutical effect
Antonio Alcami Pertejo, Madrid (ES); Sergio Martín Pontejo, Madrid (ES); and Carolina Sánchez Fernández, Madrid (ES)
Assigned to CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, Madrid (ES)
Appl. No. 17/294,582
Filed by CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS, Madrid (ES)
PCT Filed Oct. 29, 2019, PCT No. PCT/EP2019/079492 § 371(c)(1), (2) Date May 17, 2021, PCT Pub. No. WO2020/099119, PCT Pub. Date May 22, 2020.
Claims priority of application No. 18382812 (EP), filed on Nov. 16, 2018.
Prior Publication US 2022/0002380 A1, Jan. 6, 2022
Int. Cl. C07K 14/00 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/70578 (2013.01) [A61K 39/001138 (2018.08); A61K 38/00 (2013.01)]

11 Claims

1. An isolated polypeptide comprising a variant of the amino acid sequence of SEQ ID NO: 1, wherein the variant is selected from the group consisting of the amino acid substitution A105E, the amino acid substitution L106F, and the amino acid substitutions A105E and L106F in the sequence of SEQ ID NO: 1.